Elanco (ELAN) executive Kinard granted stock, with shares withheld for taxes

Rhea-AI Filing Summary

Elanco Animal Health executive David S. Kinard reported multiple equity awards and related tax withholding transactions. On March 1, 2026 he received 19,350 employee stock options and separate grants of 33,087 and 9,470 shares of common stock at no cost. A total of 15,377 common shares were disposed of at $26.40 per share to cover tax liabilities, leaving him with 217,697 common shares directly owned. The stock options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.

Insider Trade Summary

Net Buyer: 27,180 shares

Net Buy 4 txns

Insider Kinard David S

Role SEE REMARKS

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	19,350	$0.00	$0.00
Grant/Award	Common Stock	33,087	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	15,377	$26.40	$406K
Grant/Award	Common Stock	9,470	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 19,350 shares (Direct); Common Stock — 217,697 shares (Direct)

Footnotes (3)

1. F1. Includes 648 shares acquired on April 30, 2025, 518 shares acquired on July 31, 2025, 221 shares acquired on October 31, 2025, and 252 shares acquired on January 31, 2026 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan .
2. F2. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.
3. F3. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/03/2026 - 07:16 PM Learn about SEC filing dates

FAQ

What insider transactions did Elanco (ELAN) report for David S. Kinard?

Elanco reported that executive David S. Kinard received grants of stock options and common shares, and had shares withheld to cover taxes. These transactions reflect equity-based compensation rather than open-market buying or selling activity.

How many Elanco (ELAN) stock options were granted to David S. Kinard?

David S. Kinard was granted 19,350 employee stock options on March 1, 2026. These options represent the right to buy Elanco common shares in the future, subject to a multi-year vesting schedule beginning in 2027.

How many Elanco (ELAN) common shares did David S. Kinard acquire in this Form 4?

He acquired grants of 33,087 and 9,470 Elanco common shares at no cost. These awards increase his direct equity stake, subject to vesting terms described in the footnotes to the Form 4 filing.

Why were some Elanco (ELAN) shares disposed of in David S. Kinard’s filing?

A total of 15,377 common shares were disposed of at $26.40 per share to satisfy tax obligations. This tax-withholding disposition is a common method for covering taxes on vested equity awards.

What is David S. Kinard’s Elanco (ELAN) share ownership after these transactions?

Following the reported grants and tax-withholding disposition, David S. Kinard directly owns 217,697 Elanco common shares. This figure reflects his updated direct holdings as of the March 1, 2026 transactions.

When do David S. Kinard’s new Elanco (ELAN) equity awards vest?

Both the restricted stock units and stock options vest in three equal installments. Vesting occurs on March 1, 2027, March 1, 2028, and March 1, 2029, aligning compensation with longer-term company performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kinard David S

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		33,087	A	$0	223,604(1)	D
Common Stock	03/01/2026		F		15,377	D	$26.4	208,227	D
Common Stock	03/01/2026		A		9,470(2)	A	$0	217,697	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$26.4	03/01/2026		A		19,350		(3)	03/01/2036	Common Stock	19,350	$0	19,350	D

Explanation of Responses:

1. Includes 648 shares acquired on April 30, 2025, 518 shares acquired on July 31, 2025, 221 shares acquired on October 31, 2025, and 252 shares acquired on January 31, 2026 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan .

2. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

3. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

Remarks:

Executive Vice President, Human Resources, Corporate Affairs and Administration

	/s/ Amy C. Seidel, as Attorney-in-Fact for David S. Kinard	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.